BioPharma Clinical Trials
QureBio Secures Nearly CNY 100 Million in Series C1 Funding Led by Efung Capital
Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 mil...
June 06, 2025 | News
Innovent Secures Second NMPA Breakthrough Therapy Designation for IBI363 in Advanced Lung Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
June 05, 2025 | News
Akeso’s Cadonilimab Secures NMPA Approval for First-Line Treatment of Cervical Cancer
Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecif...
June 05, 2025 | News
XellSmart Advances Global Leadership in iPSC-Derived Cell Therapies for CNS Disorders
XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell the...
June 03, 2025 | News
Excyte Doses First Patient in Global Trial of YK012, the First T Cell Engager for Primary Membranous Nephropathy
Excyte, a global clinical-stage biotechnology company, announced first patient has been dosed for YK012, the world’s first patient T cell engager tha...
June 03, 2025 | News
Protagonist Therapeutics and Takeda Report Positive Phase 3 Results for Rusfertide in PV, Meeting All Primary and Secondary Endpoints
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phleboto...
June 03, 2025 | News
Huonslab Completes Patient Enrollment for Pivotal Phase 1 Trial of HLB3-002 in South Korea
Phase 1 Pivotal Study in Korea for HLB3-002 Plans to apply for marketing approval with the MFDS by the 2H 2025 -Huonslab Co., Ltd. (&ldq...
May 27, 2025 | News
Celltrion’s YUFLYMA® Wins Expanded Interchangeability Status for All Humira® Dosage Forms in the U.S.
YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar[1] Cellt...
May 26, 2025 | News
DualityBio and Avenzo Receive FDA IND Clearance for Novel EGFR/HER3 Bispecific ADC
Duality Biotherapeutics partner Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced c...
May 23, 2025 | News
Minghui Doses First Patient in Phase II Trial of PD-1xVEGF Bispecific and TROP-2 ADC Combo for Advanced NSCLC
Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, announced that ...
May 21, 2025 | News
AstraZeneca’s AIRSUPRA Cuts Severe Asthma Exacerbations by 47%, Redefines Mild Asthma Treatment Standard
AIRSUPRA demonstrated a 47% reduction in the risk of severe exacerbations in mild asthma compared with albuterol alone Full results published in th...
May 20, 2025 | News
Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment
National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...
May 19, 2025 | News
Nordic Bioscience Launches nordicEndotrophin™ to Advance Risk Stratification and Monitoring in Fibrosis and Cancer
Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrop...
May 19, 2025 | News
InnoCare Pharma Doses First Patient in Phase II/III Trial of Soficitinib for Vitiligo in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has...
May 19, 2025 | News
Most Read
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
